GlassScriptPhysician profile
Frank Tortorice
NPI 1457540551
$4,520.52
in general payments reported to CMS, 2019-2025
20 companies · $277 in 2025
The $277 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,658 · 2020: $396 · 2021: $215 · 2022: $543 · 2023: $980 · 2024: $451 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,708.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,158.61 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $710.95 | 2019-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $522.59 | 2019-2022 | |
| Exact Sciences Corporation | $422.96 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $277.51 | 2019-2025 | |
| Novo Nordisk INC | $209.18 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $193.58 | 2019-2025 | Farxiga, Breztri |
| Pfizer INC. | $132.68 | 2020-2024 | |
| Actelion Pharmaceuticals US, INC. | $125.00 | 2019 | |
| Genentech USA, INC. | $110.98 | 2022 | |
| Baxter Healthcare | $100.71 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor |
| Optinose US, INC. | $95.63 | 2019 | |
| Novartis Pharmaceuticals Corporation | $82.17 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $81.87 | 2023-2024 | Rexulti |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $81.74 | 2023 | Lifevest |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $71.66 | 2023 | Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.37 | 2023-2025 | Xifaxan |
| Allergan, INC. | $43.85 | 2019 | |
| Grt US Holding, INC. | $31.93 | 2022 | |
| Grifols USA, LLC | $21.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Tortorice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.